Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
A flat illustration of a human cell with a CRISPR tool, symbolizing gene editing.

Aug 25, 2026

New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center

Recent developments in the life sciences sector highlight significant advancements in technology and collaborations aimed at enhancing drug discovery and addressing critical health challenges.Bit.bio has introduced the ioScreen platform, a CRISPR screening service designed to facilitate human cell-based drug discovery. This platform allows researchers to manipulate gene activity, thereby deepening the understanding of disease mechanisms. Utilizing bit.bio's ioCells and other cell types, ioScreen
Press release cover image

Aug 24, 2026

Ainnocence Reports 91.4% Program Success Rate Across 58 Antibody Affinity Maturation Campaigns, Opens 28-Program Biologics Pipeline to Licensing

Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per roundAinnocence Inc., an AI-driven pharmaceutical & material IP-generatingplatform company, today reported performance results from 75 completed proteindesign programs and announced that it is seeking licensing and partneringagreements for 28 antibody, bispecific and ADC programs that have generatedpositive preclinical data across oncology, immunology and metabolicindications. Across 58a
A minimalist illustration of a pill and a molecule representing AI in drug discovery.

Aug 22, 2026

Domestic pharma industry deploying AI for drug discovery: MoS Health Anupriya Patel

At the IIMA Healthcare Summit, Minister of State for Health Anupriya Patel emphasized the transformative potential of artificial intelligence (AI) in India's pharmaceutical sector, aiming to transition from being known as the "pharmacy of the world" to becoming a "laboratory of the world."Patel highlighted the increasing integration of AI by domestic drug manufacturers to expedite the drug discovery process, indicating a shift in the industry’s focus. This technology not only aims to enhance ear
Press release cover image

Aug 21, 2026

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed CompanySHANGHAI, Aug. 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step to
A protein binder on a lab bench with scientific equipment in the background.

Aug 20, 2026

Claude Science outperforms experts in protein binder task

Anthropic's AI model, Claude Science, has demonstrated remarkable capabilities in protein design, outperforming human experts in a recent challenge.In a recent evaluation, Claude Science successfully designed protein binders for 14 out of 15 specified targets, achieving superior results compared to previous design competitions. The AI’s performance was validated through collaboration with Adaptyc Bio and Twist Bioscience, where it utilized advanced models to achieve hit rates significantly above
Press release cover image

Aug 20, 2026

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.Under the collaboration, Bristol Myers Squibb will leverage Chai’s advanced AI models and platform capabilities, including its leading molecular folding and design models, to support the discovery of antibody candidates across its portfolio and
Press release cover image

Aug 20, 2026

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraintsSHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigational ophthalmic biologic developed by Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), has received clinical trial clearance in China for neovascular age-related macular degeneration (nAMD), dia
Press release cover image

Aug 19, 2026

SandboxAQ Launches AQPotency, Bringing Ultrafast Virtual Screening to Drug Discovery Without a Solved Protein Structure

PALO ALTO, Calif., Aug. 19, 2026 /PRNewswire/ -- SandboxAQ today announced the general availability of AQPotency, its Large Quantitative Model (LQM) for predicting how well a potential drug will work, now available on Claude via Model Context Protocol (MCP). For any disease target, AQPotency scores how strongly candidate molecules are likely to act on it, and it does this without the expensive, time-consuming lab work that older methods depend on. Drug discovery teams can now rank enormous libra
Press release cover image

Aug 18, 2026

Asimov Announces Cell Line Development Partnership with Kaigene to Advance Multispecific Antibody for Autoimmune Disease

BOSTON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Kaigene, a biotechnology company pioneering next-generation antibody therapeutics for pathogenic antibody-mediated autoimmune diseases. The partnership covers a full cell line development campaign, from vector design and synthesis through the production and shipment of a high-titer research ce
A minimalist representation of a molecule and a test tube in a dark color scheme.

Aug 17, 2026

Pharma Races to Scale AI as Billions Flow into Drug Discovery

The landscape of AI-driven drug discovery is rapidly evolving, fueled by substantial investments that prioritize comprehensive platforms over individual drug assets. This shift is characterized by advanced AI reasoning workflows that enhance biomedical research across diverse datasets, including genomics and proteomics, enabling the development of more sophisticated models of biological complexity.Key players like Isomorphic Labs are leading this charge, with a focus on creating a versatile desi
A minimalist representation of a pill and a molecule in flat design.

Aug 15, 2026

Lantern Pharma Says AI Cuts First-In-Human Drug Development Cost To $2 Million-$3 Million

Lantern Pharma has reported a significant reduction in the costs associated with advancing oncology programs to first-in-human clinical trials, utilizing its AI-driven drug development model. The company claims that this approach allows for development costs to be as low as $2 million to $3 million per program, a stark contrast to the industry standard of $25 million to $100 million.The company's RADR platform leverages artificial intelligence and machine learning to expedite the drug developmen
Press release cover image

Aug 15, 2026

Aizen Enters into Collaboration with San Diego Biopharma to Advance Oral Biologics

Multi-program deal with revenue potential of $100 million per targetSAN DIEGO, Aug. 15, 2026 /PRNewswire/ -- Aizen Therapeutics, an AI-native biotechnology company focused on building oral biologics, today announced a multi-program collaboration with a San Diego-based, public biotech to design oral peptide therapeutics using its DaX™ foundation model. The agreement provides Aizen with several million dollars in initial revenue and up to $100 million in milestones for each nominated target."Oral